Skip to content

Released May 2, 2019, after the close

10-Q filed May 7, 2019, 37 days after period end · 0001162194-19-000033

Q1 2019 · 10-Q
Revenue$30.11M+19.3% vs Q1 2018−6.8% vs Q4 2018
Net Income-$25.47MN/M vs Q1 2018N/M vs Q4 2018
EPS Diluted-$0.44N/M vs Q1 2018N/M vs Q4 2018
Gross Profit$16,990,000+26.5%
Operating Income-$14,206,000N/M
Operating Cash Flow-$20,130,000N/M
Free Cash Flowderived-$20,396,000N/M
Margins · derived
Gross margin56.4%+3.2 pt vs Q1 2018
Operating margin-47.2%+2.9 pt vs Q1 2018
Net margin-84.6%−32.1 pt vs Q1 2018

What the release said

The release

Same quarter

MetricQ1 2019Q1 2018Q1 2017Q1 2016
Revenue$30.11M$25.25M$25.53M$29.00M
Net Income-$25.47M-$13.25M-$17.20M-$19.88M
EPS Diluted-$0.44-$0.34-$0.59-$0.69

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR